NeoGenomics Inc (NEO)

Gross profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Gross profit (ttm) US$ in thousands 244,604 233,841 220,423 204,478 187,896 176,328 174,674 183,718 187,060 199,256 206,082 181,098 185,893 178,363 175,130 196,090 196,836 184,024 165,513 147,077
Revenue (ttm) US$ in thousands 601,638 580,487 554,336 529,041 507,523 493,983 486,680 484,258 482,622 482,400 486,504 451,757 442,254 425,319 404,547 419,283 408,830 378,437 342,861 308,894
Gross profit margin 40.66% 40.28% 39.76% 38.65% 37.02% 35.70% 35.89% 37.94% 38.76% 41.31% 42.36% 40.09% 42.03% 41.94% 43.29% 46.77% 48.15% 48.63% 48.27% 47.61%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $244,604K ÷ $601,638K
= 40.66%

Neogenomics Inc.'s gross profit margin has shown a positive trend over the last eight quarters, indicating an improvement in the company's ability to generate profit from its core operations. The margin has consistently increased from 35.70% in Q2 2022 to 41.34% in Q4 2023. This indicates that the company has been able to effectively control its cost of goods sold and/or increase the prices of its products and services.

The steady improvement in gross profit margin reflects positively on Neogenomics Inc.'s operational efficiency and pricing strategy. It suggests that the company may have implemented cost-saving measures, negotiated better terms with suppliers, or introduced higher-margin services or products. Overall, the upward trend in the gross profit margin indicates that the company's financial performance in terms of generating gross profit has been strengthening steadily over the past eight quarters.